abcam

ab33330

FITC Anti-HLA B7 antibody [BB7.1]

Anti-HLA B7 antibody [BB7.1] conjugated to FITC - suitable for flow cytometry, and reacts with human, Crab-Eating Macaque samples. Clone [BB7.1] is a mouse monoclonal antibody cited in 14 publications.

Design your panel with our interactive flow cytometry panel builder. Click here.

Key facts

Isotype	IgG1
Host species	Mouse
Conjugation	FITC
Excitation/Emission	Ex: 495nm, Em: 519nm
Storage buffer	pH: 7.4 Preservative: 0.09% Sodium azide Constituents: PBS, 1% BSA
Form	Liquid
Clonality	Monoclonal
Immunogen	Full Length Protein corresponding to Human HLA-B. The exact immunogen used to generate this antibody is proprietary information. Database link P01889
Clone number	BB7.1
Purification technique	Affinity purification Protein G
Specificity	This antibody recognizes the HLA B7 antigen and does not cross react with HLA B27 or other related antigens.
Concentration	0.1 mg/mL The concentration of this product may be batch-dependent Batch concentration finder →
Purification notes	This antibody was purified from tissue culture supernatant.

Reactivity data

Flow Cyt

Tested

Species	Human
Dilution info	1/1 - 1/10
Notes	Use 10µl of the suggested working dilution to label 10^6 cells or 100µl whole blood. ab91356 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.

Expected

Species	Cynomolgus monkey
Dilution info	1/1 - 1/10
Notes	Use 10µl of the suggested working dilution to label 10^6 cells or 100µl whole blood. ab91356 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.

Target data

See full target information HLA-B

Function

Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumor-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-B-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells (PubMed:23209413, PubMed:25808313, PubMed:29531227, PubMed:9620674). May also present self-peptides derived from the signal sequence of secreted or membrane proteins, although T cells specific for these peptides are usually inactivated to prevent autoreactivity (PubMed:18991276, PubMed:7743181). Both the peptide and the MHC molecule are recognized by TCR, the peptide is responsible for the fine specificity of antigen recognition and MHC residues account for the MHC restriction of T cells (PubMed:24600035, PubMed:29531227, PubMed:9620674). Typically presents intracellular peptide antigens of 8 to 13 amino acids that arise from cytosolic proteolysis via constitutive proteasome and IFNG-induced immunoproteasome (PubMed:23209413). Can bind different peptides containing allele-specific binding motifs, which are mainly defined by anchor residues at position 2 and 9 (PubMed:25808313, PubMed:29531227). Allele B*07:02: Displays peptides sharing a common signature motif, namely a Pro residue at position 2 and mainly a Leu anchor residue at the C-terminus (PubMed:7743181). Presents a long peptide (APRGPHGGAASGL) derived from the cancer-testis antigen CTAG1A/NY-ESO-1, eliciting a polyclonal CD8-positive T cell response against tumor cells (PubMed:29531227). Presents viral epitopes derived from HIV-1 gag-pol (TPQDLNTML) and Nef (RPQVPLRPM) (PubMed:25808313). Presents an immunodominant epitope derived from SARS-CoV-2 N/nucleoprotein (SPRWYFYYL)

(PubMed:32887977). Displays self-peptides including a peptide derived from the signal sequence of HLA-DPB1 (APRTVALTA) (PubMed:7743181). Allele B*08:01: Presents to CD8-positive T cells viral epitopes derived from EBV/HHV-4 EBNA3 (QAKWRLQTL), eliciting cytotoxic T cell response. Allele B*13:02: Presents multiple HIV-1 epitopes derived from gag (RQANFLGKI, GQMREPRGSDI), nef (RQDILDLWI), gag-pol (RQYDQILIE, GQGQWTYQI) and rev (LQLPPLERL), all having in common a Gln residue at position 2 and mainly hydrophobic amino acids Leu, Ile or Val at the C-terminus. Associated with successful control of HIV-1 infection. Allele B*18:01: Preferentially presents octameric and nonameric peptides sharing a common motif, namely a Glu at position 2 and Phe or Tyr anchor residues at the C-terminus (PubMed:14978097, PubMed:18991276, PubMed:23749632). Presents an EBV/HHV-4 epitope derived from BZLF1 (SELEIKRY) (PubMed:23749632). May present to CD8-positive T cells an antigenic peptide derived from MAGEA3 (MEVDPIGHLY), triggering an anti-tumor immune response (PubMed:12366779). May display a broad repertoire of self-peptides with a preference for peptides derived from RNA-binding proteins (PubMed:14978097). Allele B*27:05: Presents to CD8-positive T cells immunodominant viral epitopes derived from HCV POLG (ARMILMTHF), HIV-1 gag (KRWIILGLNK), IAV NP (SRYWAIRTR), SARS-CoV-2 N/nucleoprotein (QRNAPRITF), EBV/HHV-4 EBNA4 (HRCQAIRKK) and EBV/HHV-4 EBNA6 (RRIYDLIEL), conferring longterm protection against viral infection (PubMed:15113903, PubMed:18385228, PubMed:19139562, PubMed:32887977, PubMed:9620674). Can present self-peptides derived from cytosolic and nuclear proteins. All peptides carry an Arg at position 2 (PubMed:1922338). The peptide-bound form interacts with NK cell inhibitory receptor KIR3DL1 and inhibits NK cell activation in a peptide-specific way, being particularly sensitive to the nature of the amino acid side chain at position 8 of the antigenic peptide (PubMed:15657948, PubMed:8879234). KIR3DL1 fails to recognize HLA-B*27:05 in complex with B2M and EBV/HHV-4 EBNA6 (RRIYDLIEL) peptide, which can lead to increased activation of NK cells during infection (PubMed:15657948). May present an altered repertoire of peptides in the absence of TAP1-TAP2 and TAPBPL (PubMed:9620674). Allele B*40:01: Presents immunodominant viral epitopes derived from EBV/HHV-4 LMP2 (IEDPPFNSL) and SARS-CoV-2 N/nucleoprotein (MEVTPSGTWL), triggering memory CD8-positive T cell response (PubMed:18991276, PubMed:32887977). Displays self-peptides sharing a signature motif, namely a Glu at position 2 and a Leu anchor residue at the C-terminus (PubMed:18991276). Allele B*41:01: Displays self-peptides sharing a signature motif, namely a Glu at position 2 and Ala or Pro anchor residues at the C-terminus. Allele B*44:02: Presents immunodominant viral epitopes derived from EBV/HHV-4 EBNA4 (VEITPYKPTW) and EBNA6 (AEGGVGWRHW, EENLLDFVRF), triggering memory CD8-positive T cell response (PubMed:18991276, PubMed:9620674). Displays self-peptides sharing a signature motif, namely a Glu at position 2 and Phe, Tyr or Trp anchor residues at the C-terminus (PubMed:18991276). Allele B*45:01: Displays self-peptides sharing a signature motif, namely a Glu at position 2 and Ala or Pro anchor residues at the C-terminus. Allele B*46:01: Preferentially presents nonameric peptides sharing a signature motif, namely Ala and Leu at position 2 and Tyr, Phe, Leu, or Met anchor residues at the C-terminus. The peptide-bound form interacts with KIR2DL3 and inhibits NK cell cytotoxic response in a peptide-specific way. Allele B*47:01: Displays self-peptides sharing a signature motif, namely an Asp at position 2 and Leu or Met anchor residues at the C-terminus. Allele B*49:01: Displays self-peptides sharing a signature motif, namely a Glu at position 2 and Ile or Val anchor residues at the C-terminus. Allele B*50:01: Displays self-peptides sharing a signature motif, namely a Glu at position 2 and Ala or Pro anchor residues at the C-terminus. Allele B*51:01: Presents an octameric HIV-1 epitope derived from gag-pol (TAFTIPSI) to the public TRAV17/TRBV7-3 TCR clonotype, strongly suppressing

HIV-1 replication. Allele B*54:01: Displays peptides sharing a common signature motif, namely a Pro residue at position 2 and Ala anchor residue at the C-terminus. Allele B*55:01: Displays peptides sharing a common signature motif, namely a Pro residue at position 2 and Ala anchor residue at the C-terminus. Allele B*56:01: Displays peptides sharing a common signature motif, namely a Pro residue at position 2 and Ala anchor residue at the C-terminus. Allele B*57:01: The peptide-bound form recognizes KIR3DL1 and inhibits NK cell cytotoxic response. Presents HIV gag peptides (immunodominant KAFSPEVIPMF and subdominant KALGPAATL epitopes) predominantly to CD8-positive T cell clones expressing a TRAV41-containing TCR, triggering HLA-B-restricted T cell responses. Allele B*67:01: Displays peptides sharing a common signature motif, namely a Pro residue at position 2 and Leu anchor residue at the C-terminus.

Storage

Shipped at conditions	Blue Ice
Appropriate short-term storage conditions	+4°C
Appropriate long-term storage conditions	+4°C

Notes

This antibody can be used to distinguish true HLA B27 positives from false HLA B27 positives (i.e. HLA B7 positive) in the investigation of diseases such as ankylosing spondylitis and anterior uveitis.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary	HLA-B7 also known as HL-A B7 is a part of the human leukocyte antigen (HLA) system and belongs to the HLA class I heavy chain paralogs. This protein has a molecular mass of approximately 45 kDa. HLA-B7 is expressed on the surface of nearly all nucleated cells in the body. Its main role is to present peptide antigens to the immune system specifically to cytotoxic T cells which play an important part in immune response.
Biological function summary	HLA-B7 is involved in antigen presentation as a part of the major histocompatibility complex (MHC) class I molecule. HLA-B7 like other HLA class I molecules presents endogenous peptides to CD8+ T cells. The HLA B27 pair although different from HLA-B7 shares functional similarities that influence immune surveillance and activation processes.
Pathways	HLA-B7 participates in the antigen processing and presentation pathway. This pathway allows the presentation of intracellularly derived peptides at the cell

	surface which are recognized by T cell receptors (TCR) on CD8+ T lymphocytes. HLA-B7 works in concert with proteasomes for peptide generation and with transporter associated with antigen processing (TAP) for delivering peptides to the endoplasmic reticulum.
Associated diseases and disorders	HLA-B7 is linked with certain autoimmune diseases and viral infections. Some studies suggest an association with increased susceptibility to diseases such as sarcoidosis. Moreover individuals who are HLA-B7 positive may differ in their immune response to viral infections like HIV. The interaction between HLA-B7 and proteins like beta-2 microglobulin further affects its role in disease mechanisms and immune function.

Product promise

Tested

We have tested this species and application combination and it works. It is covered by our product promise.

Expected

We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.

Predicted

This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.

Not recommended


We do not recommend this combination. It is not covered by our product promise.

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

1 product image



Flow Cytometry - FITC Anti-HLA B7 antibody [BB7.1] (ab33330)

HLA B7 Flow Cytometry staining using mouse Anti-HLA B7 antibody

Staining of human peripheral blood lynphocytes with ab33330

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.